Ubiquitin Enzymes: Key Targets and Future Market Potential, 2016-2030

  • ID: 3989425
  • Report
  • Region: Global
  • 242 Pages
  • Roots Analysis
1 of 5
Provides an Extensive Study on the Current Landscape of the Evolving Pipeline of Ubiquitin Enzyme Inhibitors and Offers a Comprehensive Discussion on the Future Potential of this Market

FEATURED COMPANIES

  • 3SBio
  • BostonBiochem
  • EG Capital Group
  • Invenio Therapeutics
  • Novitas Capital
  • Selleckchem
  • MORE

The ubiquitin proteasome system (UPS) is one of the key protein degradation pathway involved in the control of protein homeostasis and turnover that mediates the regulation of several cellular processes. The UPS consists of two separate consecutive steps, ubiquitination and proteasomal degradation. Due to its involvement in multiple metabolic and regulatory functions, the UPS is considered as a vital part of the cellular machinery controlling protein homeostasis.

Targeting specific components of the UPS in order to regulate cellular growth and metabolism in diseases is not a novel concept; however, advances in molecular signalling have revealed a number of potential enzyme targets within the UPS that, if successfully modulated, can lead to the development of highly specific drugs against a number of pathological and degenerative disease indications.

Many scientists and research groups are trying to unravel the hidden potential of this highly complex regulatory system in...

A number of technical advances in this domain have led to the development of multiple technology platforms, research based assays, toolkits, probes, reagents and precursor compounds to support the different drug discovery programs of various academic and industry researchers. In fact, the current market landscape features contributions of not only big pharma companies but also small to mid-sized players and academic institutions.

A number of strategic partnerships have also been inked between various stakeholders to advance R&D activities in this domain. Results of preclinical and clinical studies have demonstrated the potential benefits of this class of therapies; the major highlight being their attractive safety profile. The burgeoning field of research has captured the interest of several venture capital firms and strategic investors. The upcoming market, primarily focused on oncological indications, is expected to prosper in the long term and witness the emergence of several successful drugs.

The "Ubiquitin Enzymes: Key Targets and Future Market Potential, 2016-2030" report provides an extensive study on the current landscape of the evolving pipeline of ubiquitin enzyme inhibitors and offers a comprehensive discussion on the future potential of this market.

Ubiquitin enzymes have been implicated in various cellular processes, such as protein homeostasis, apoptosis, autophagy, DNA damage repair, cell cycle control and senescence. Due to their involvement in multiple metabolic and regulatory functions, any deviations in the normal functioning of the UPS has been shown to lead to the development of diverse types of diseases.
 
Initial research on the UPS led to the development of several proteasome inhibitors, such as Velcade®, Kyprolis® and Ninlaro®, which are already available in different regions across the globe. However, since these drugs target the entire protein degradation pathway, lack of target specificity renders them potentially harmful and their use has been shown to pose side effects in patients.

Consequently, the focus is gradually shifting from proteasome inhibitors to targeting specific components of the UPS, primarily on ubiquitination enzymes. This is a relatively new segment of the overall market. With no marketed products, the UPS associated enzyme inhibitors/modulators market is still in its infancy. The report primarily focuses on four classes of enzymes that have been shown to possess therapeutic relevance; these include E1 activating enzymes, E2 conjugating enzymes, E3 ligases and deubiquitinases (DUBs).
 
Currently, the ubiquitin pathway based inhibitors pipeline comprises of over 45 molecules that are under development for the treatment of a variety of indications. In addition, there are several companies that are engaged in the development of screening and validation assays for lead selection, research tools and competent technologies in this field. This unexploited and promising market has its hopes pinned on multiple start-ups, which have received significant financial support from several strategic investors and venture capital firms over the last few years.

Among other elements, the report provides the following information:

  • The current state of the market with respect to the key players, phase of development of pipeline products (both clinical and preclinical/discovery), target enzyme classes and the key disease indications.
  • Comprehensive profiles highlighting clinical trial details, key preclinical/clinical findings and future market opportunity for the clinical stage (phase I/II, phase II and phase III) ubiquitin enzyme inhibitors.
  • Various investments and grants received by companies focused in this area in order to accelerate and support their R&D activities.
  • Partnerships that have taken place in the recent past covering product development/commercialization agreements, research collaborations, clinical trial collaborations, license agreements, acquisitions and other such deals between stakeholders in the industry.

One of the key objectives of this report was to understand the current activity and the future potential of the market. The study provides a detailed market forecast and opportunity analysis for the period between 2016 and 2030. The research, analysis and insights presented in this report include a detailed description of ubiquitin enzyme inhibitors along with drug classes closely associated with them.

To add robustness to our model, we have provided three scenarios for our market forecast, namely the conservative, base and optimistic scenarios, to account for future uncertainties. The opinions and insights presented in this study were influenced by several discussions conducted with experts in this domain. All actual figures have been sourced and analyzed from publicly available information forums and from primary research. All financial figures mentioned in this report are in USD, unless otherwise specified.

Example Highlights

  • Over 45 molecules targeting ubiquitin enzymes are currently in clinical/preclinical stages of development. 71% of the pipeline molecules are targeting oncological indications. Within oncology, hematological malignancies, such as acute myeloid leukemia (AML) and relapsed/refractory multiple myeloma (MM), are the primary focus areas. In fact, the two late stage molecules, idasanutlin and pevonedistat, are being developed for hematological cancers. Other indications such as Alzheimer’s disease, Parkinson’s disease, Friedreich's ataxia and Angelman syndrome are also gradually gaining interest of developers.
  • The innovation in this emerging field is primarily being led by start-ups/small companies. Notable examples include (in alphabetical order) Agilis Biotherapeutics, Aileron Therapeutics, Almac Discovery, Aperion Biologics, Ascenta Therapeutics, Carmot Therapeutics, CellCentric, Cleave Biosciences, Ensemble Therapeutics, Mission Therapeutics, Progenra, Proteostasis Therapeutics, UbiQ Therapeutics, and Vivolux. In addition, a number of large companies are also developing assets in this field. Prominent players under this category include (in alphabetical order) Amgen, Biogen, Daiichi Sankyo, Merck, Novartis Pharmaceuticals, Priaxon, Roche/Genentech, Sanofi and Servier.
  • Prominent academic players, including (in alphabetical order) the Dana-Farber Cancer Institute, Karolinska Institute, Mayo Clinic, Memorial Sloan Kettering Cancer Center, University of Oxford and University of Michigan, have entered into research collaborations with industry players to conduct further research for the development of various inhibitors.
  • Several strategic investors and venture capitalists have strongly backed the potential offered by this domain. We identified over 70 funding instances over the past few years. The total amount invested has been close to USD 1.2 billion; of this, 70% has been invested during the last five years alone.
  • Stakeholders have actively collaborated to advance R&D initiatives. We came across 71 collaborations categorized as product development/commercialization agreements, product licensing agreements, technology licensing, acquisitions, clinical trial agreements and research collaborations. Among these, development/commercialization agreements and research collaborations, with over 60% share, have been the most popular.
  • In addition, we came across around 20 technology/research platforms that are currently available to advance the development of ubiquitin enzyme inhibitors. It is worth mentioning that these platforms are a direct consequence of the intense research activity in this field. Examples include (in alphabetical order) DUBprofiler™, DUBprofiler™, PROTAC Technology Platform, Ubi-Plex™ and UbiPro™.
  • Overall, we expect the field to witness considerable success in the long term. Post the launch of the first wave of products, we predict the market to grow at an annualized rate of 75% till 2030.
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • 3SBio
  • BostonBiochem
  • EG Capital Group
  • Invenio Therapeutics
  • Novitas Capital
  • Selleckchem
  • MORE

1. Preface
1.1. Chapter Overview
1.2. Research Methodology
1.3. Chapter Outlines
 
2. Executive Summary
 
3. Introduction
3.1. Chapter Overview
3.2. The Concept of Protein Homeostasis
3.3. Importance of Post Translational Modifications in Cellular Functions
3.4. Discovery of the Ubiquitin/Ubiquitin Proteasome System
3.5. Ubiquitin: Structure and Function
3.6. Fundamentals of the UPS
3.6.1. Components of the UPS
3.6.2. Key Steps Involved in the UPS
3.7. Therapeutic Applications of UPS
3.8. Emergence of Ubiquitin Enzyme Inhibitors
 
4. Ubiquitin Enzyme Inhibitors: Market Overview
4.1. Chapter Overview
4.2. Ubiquitin Enzyme Inhibitors: Development Pipeline
4.3. Ubiquitin Enzyme Inhibitors: Distribution by Phase of Development
4.4. Ubiquitin Enzyme Inhibitors: Distribution by Therapeutic Area
4.5. Ubiquitin Enzyme Inhibitors: Distribution by Target Ubiquitin Enzymes
4.6. Ubiquitin Enzyme Inhibitors: Distribution by Geography
4.7. Ubiquitin Enzyme Inhibitors: Most Active Industry Players
4.8. Ubiquitin Enzyme Inhibitors: Research Tools, Key Technologies and Precursor Compounds
4.8.1. Research Tools/Key Technologies
4.8.2. Precursor Compounds
4.8.3. UPS Based Research Tools: Other Players
 
5. Key Insights: Therapeutic Areas and Potential Targets
5.1. Chapter Overview
5.2. Ubiquitin Enzyme Inhibitors Clinical Development Analysis: Therapeutic Areas
5.3. Ubiquitin Enzyme Inhibitors Clinical Development Analysis: Potential Targets
5.4. Ubiquitin Enzyme Inhibitors Clinical Development Analysis: Developer Landscape
5.5. Developers of Ubiquitin Enzyme Inhibitors: Geographical Presence
5.6. Ubiquitin Enzyme Inhibitors and UPS: Recent/Upcoming Conferences
 
6. E1 and E2 Enzymes as Therapeutic Targets
6.1. Chapter Overview
6.2. E1 Activating Enzymes as Drug Targets
6.2.1. E1 Enzymes: An Introduction
6.2.2. E1 Enzymes: Mechanism of Action
6.2.3. E1 Enzyme Inhibitors: List of Related Targets
6.2.4. E1 Enzyme Inhibitors: Development Pipeline
6.2.5. E1 Enzyme Inhibitors: Drug Profiles
6.2.6. E1 Enzyme Inhibitors Development: Challenges and Opportunities
 
6.3. E2 Conjugating Enzymes as Drug Targets
6.3.1. E2 Enzymes: An Introduction
6.3.2. E2 Enzymes: Mechanism of Action
6.3.3. E2 Enzyme Inhibitors: List of Related Targets
6.3.4. E2 Enzyme Inhibitors: Development Pipeline
6.3.5. E2 Enzyme Inhibitors Development: Challenges and Opportunities
 
7. E3 Enzymes as Therapeutic Targets
7.1. Chapter Overview
7.2. E3 Ligases: An Introduction
7.3. E3 Ligases: Mechanism of Action
7.4. E3 Ligases: Important Families
7.4.1. The RING Family
7.4.2. The HECT Family
7.4.3. SCF Complex
7.4.4. U-Box Family
7.4.5. RBR Family
7.5. E3 Ligase Inhibitors: List of Related Targets
7.6. E3 Ligase Inhibitors: Screening Methods
7.7. E3 Ligase Inhibitors: Development Pipeline
7.8. E3 Ligase Inhibitors: Drug Profiles
 
7.8.1. Idasanutlin/RG 7388/RO 5503781 (Roche)
7.8.1.1. Drug Specifications
7.8.1.2. Mechanism of Action
7.8.1.3. Current Status of Development
7.8.1.4. Key Clinical Trials
7.8.1.5. Key Preclinical/Clinical Findings
 
7.8.2. AMG 232 (Amgen)
7.8.2.1. Drug Specifications
7.8.2.2. Mechanism of Action
7.8.2.3. Current Status of Development
7.8.2.4. Key Clinical Trials
7.8.2.5. Key Preclinical/Clinical Findings
 
7.8.3. HDM201/NVP-HDM201 (Novartis Pharmaceuticals)
7.8.3.1. Drug Specifications
7.8.3.2. Mechanism of Action
7.8.3.3. Current Status of Development
7.8.3.4. Key Clinical Trials
7.8.3.5. Key Preclinical/Clinical Findings
 
7.9. E3 Ligase Inhibitors: Challenges and Opportunities
 
8. DUB Enzymes as Therapeutic Targets
8.1. Chapter Overview
8.2. DUBs: An Introduction
8.3. DUBs: Mechanism of Action
8.4. DUBs: Important Families
8.4.1. USP/UBP Family
8.4.2. UCH Family
8.4.3. MCPIP Family
8.4.4. OTU Family
8.4.5. MJD Family
8.4.6. JAMM Family
8.5. DUB Inhibitors: List of Related Targets
8.6. DUB Inhibitors: Screening Methods
8.7. DUB Inhibitors: Development Pipeline
8.8. DUB Inhibitors: Drug Profiles
8.9. DUB Inhibitors Development: Challenges and Opportunities
 
9. Associated Drug Classes
9.1. Chapter Overview
9.2. Proteasome Inhibitors
9.3. Immunomodulatory Drugs
9.4. IAP Inhibitors
 
10. Venture Capital Interest
10.1. Chapter Overview
10.2. Funding Instances: Distribution by Type of Funding
10.3. Funding Instances for Development of Ubiquitin Based Therapeutics
10.4. Rising Venture Capital Interest
10.5. Leading Players: Distribution by Number of Funding Instances
10.6. Most Active Venture Capital Firms/Investors
10.7. Funding Instances: Distribution by Focus Area
 
11. Recent Collaborations
11.1. Chapter Overview
11.2. Partnership Models/Agreements
11.3. UPS Based Therapeutics: Recent Collaborations
11.4. Recent Collaborations: Distribution by Month/Year
11.5. Recent Collaborations: Distribution by Type of Model
11.6. Recent Collaborations: Distribution by Focus Area
11.7. Recent Collaborations: Most Active Companies
 
12. Market Forecast and Opportunity Analysis
12.1. Chapter Overview
12.2. Scope and Limitations
12.3. Forecast Methodology
12.4. Overall Ubiquitin Enzyme Inhibitors Market
12.5. Ubiquitin Enzyme Inhibitors Market: Individual Forecasts
 
12.5.1. Idasanutlin (Genentech)
12.5.1.1. Target Patient Population
12.5.1.2. Sales Forecast
 
12.5.2. Pevonedistat (Millennium Pharmaceuticals)
12.5.2.1. Target Patient Population
12.5.2.2. Sales Forecast
 
12.5.3. HDM201 (Novartis Pharmaceuticals)
12.5.3.1. Target Patient Population
12.5.3.2. Sales Forecast
 
12.5.4. VLX1570 (Vivolux)
12.5.4.1. Target Patient Population
12.5.4.2. Sales Forecast
 
12.5.5. AMG 232 (Amgen)
12.5.5.1. Target Patient Population
12.5.5.2. Sales Forecast
 
13. Conclusion
13.1. Drugs Targeting Protein Modification Pathways Have Emerged as Valuable Therapeutic Options
13.2. Extensive Research is Being Carried Out to Address the Challenges Associated with Drug Discovery
13.3. The Evolving Pipeline Caters to a Wide Spectrum of Disease Indications
13.4. Targeted Therapies are Being Developed by Leveraging Inherent Specificity of Various UPS Components
13.5. Growing Partnerships and VC Support are Indicative of Lucrative Future Potential
13.6. Novel Technology Platforms and Therapeutic Concepts Will Act as Key Enablers to Drive Future Growth
13.7. Once Approved, Ubiquitin Enzyme Inhibitors are Poised to Achieve an Accelerated Growth
 
14. Interview Transcripts
14.1. Chapter Overview
14.2. Martin Wiles, Vice President Business Development and Licensing, Almac Discovery
 Gerald Gavory, Director of Biology, Almac Discovery
14.3. Katrin Rittinger, Research Group Leader, Francis Crick Institute
14.4. Zhihao Zhuang, Associate Professor, Department of Chemistry and Biochemistry, University Of Delaware
 
15. Appendix 1: Tabulated Data
 
16. Appendix 2: List Of Companies And Organizations

List of Figures

Figure 3.1 Protein Surveillance: Important Mechanisms
Figure 3.2 Post Translational Modifications: Common Types
Figure 3.3 Phosphorylation and Ubiquitination: Key Differences in Drug Discovery
Figure 3.4 Phosphorylation and Ubiquitination: Mechanism based Analogies
Figure 3.5 Ubiquitin: Types of Target Proteins
Figure 3.6 Genetic Evolution of the UPS in Eukaryotes
Figure 3.7 Key Components of the UPS
Figure 3.8 Ubiquitin-Proteasome Pathway
Figure 3.9 Modes of Ubiquitination
Figure 3.10 Ubiquitination: Biological Functions
Figure 3.11 UPS: Disease Development Process
Figure 3.12 UPS: Key Therapeutic Areas
Figure 4.1 Ubiquitin Enzyme Inhibitors: Distribution by Phase of Development
Figure 4.2 Ubiquitin Enzyme Inhibitors: Distribution by Therapeutic Area
Figure 4.3 Ubiquitin Enzyme Inhibitors: Distribution by Target Enzymes
Figure 4.4 Ubiquitin Enzyme Inhibitors: Distribution by Target Ubiquitin Enzymes and Phase of Development
Figure 4.5 Ubiquitin Enzyme Inhibitors: Distribution by Geography
Figure 4.6 Ubiquitin Enzyme Inhibitors: Regional Landscape
Figure 4.7 Ubiquitin Enzyme Inhibitors: Most Active Industry Players
Figure 4.8 UPS Based Research Tools: Other Market Participants
Figure 5.1 Grid Analysis: Distribution by Target Enzyme Class, Therapeutic Area and Phase of Development
Figure 5.2 Ubiquitin Enzyme Inhibitors Funnel Analysis: Distribution by Target Enzyme Class and Phase of Development
Figure 5.3 Ubiquitin Enzyme Inhibitors Developer Landscape: Distribution by Developer and Phase of Development
Figure 5.4 Ubiquitin Enzyme Inhibitors: Geographical Presence
Figure 5.5 Recent/Upcoming Conferences: Distribution by Year and Geography
Figure 5.6 Recent/Upcoming Conferences: Regional Map
Figure 6.1 E1 Activating Enzymes: List of Related Targets
Figure 6.2 E1 Enzyme Drug Development: Major Challenges
Figure 6.3 E2 Enzymes: List of Related Targets
Figure 6.4 E2 Enzyme Drug Development: Major Challenges
Figure 7.1 Mechanism of Action: RING, HECT and U-Box Families
Figure 7.2 E3 Ligases: Important Families
Figure 7.3 Tumor Suppression by p53
Figure 7.4 Different Types of MDM2-p53 Interactions
Figure 7.5 MDM2 Mediated p53 Degradation Pathway
Figure 7.6 E3 Ligases: List of Related Targets
Figure 7.7 E3 Ligases: Screening Methods
Figure 7.8 E3 Ligase Drug Development: Major Challenges
Figure 8.1 DUB Enzymes: Important Families
Figure 8.2 DUB Enzymes: List of Related Targets
Figure 8.3 DUB Enzymes: Screening Methods
Figure 8.4 DUB Drug Development: Major Challenges
Figure 9.1 Proteasome Inhibitors: Related Side Effects
Figure 9.2 IAP Pathways and SMAC Mimetics
Figure 10.1 Funding Instances: Number of Instances, 2006-2016
Figure 10.2 Funding Instances: Amount Invested, 2006-2016 (USD Million)
Figure 10.3 Funding Instances: Distribution by Type, 2006-2016
Figure 10.4 Funding Instances: Distribution by Total Amount Invested, 2006-2016 (USD Million)
Figure 10.5 Funding Instances: Distribution by Range of Amount Invested by Type of Funding (USD Million)
Figure 10.6 Most Active Players: Distribution by Number of Funding Instances, 2006-2016
Figure 10.7 Most Active Venture Capital Firms/Investors: Distribution by Number of Instances, 2006-2016
Figure 10.8 Funding Instances: Distribution by Focus Area
Figure 11.1 Recent Collaborations: Distribution by Year
Figure 11.2 Recent Collaborations: Distribution by Type of Model
Figure 11.3 Recent Collaborations: Distribution by Focus Area
Figure 11.4 Recent Collaborations: Distribution by Focus Area and Partnership Model
Figure 11.5 Recent Collaborations: Most Active Players
Figure 12.1 Overall Ubiquitin Enzyme Inhibitors Market (USD Million): 2016-2030 (Base Scenario)
Figure 12.2 Ubiquitin Enzyme Inhibitors Market: Distribution by Therapeutic Area, 2025, 2030 (USD Million)
Figure 12.3 Ubiquitin Enzyme Inhibitors Market: Distribution by Target Enzyme Class, 2030 (USD Million)
Figure 12.4 Ubiquitin Enzyme Inhibitors: Distribution of Market Share, 2030 (USD Million)
Figure 12.5 Idasanutlin Sales Forecast (USD Million), Base Scenario
Figure 12.6 Pevonedistat Sales Forecast (USD Million), Base Scenario
Figure 12.7 HDM201 Sales Forecast (USD Million), Base Scenario
Figure 12.8 VLX1570 Sales Forecast (USD Million), Base Scenario
Figure 12.9 AMG 232 Sales Forecast (USD Million), Base Scenario
Figure 13.1 Overall Ubiquitin Enzyme Inhibitors Market Summary (USD Million):2016, 2023, 2030

List of Tables

Table 3.1 Ubiquitin: Structural Classification
Table 4.1 Ubiquitin Enzyme Inhibitors: Development Pipeline
Table 4.2 Ubiquitin Enzyme Inhibitors: Research Platforms
Table 4.3 Ubiquitin Enzyme Inhibitors: Precursor Compounds
Table 5.1 Ubiquitin Enzyme Inhibitors and UPS: Recent/Future Conferences, 2013-2017
Table 6.1 E1 Enzyme Inhibitors: Development Pipeline
Table 6.2 Pevonedistat: Current Status of Development
Table 6.3 Pevonedistat: Clinical Trials
Table 6.4 E2 based Inhibitors: Development Pipeline
Table 7.1 SCF Complex: Core Components
Table 7.2 E3 Ligase based Therapeutics: Development Pipeline
Table 7.3 Idasanutlin: Current Status of Development
Table 7.4 Idasanutlin: Clinical Trials
Table 7.5 AMG 232: Current Status of Development
Table 7.6 AMG 232: Clinical Trials
Table 7.7 HDM201: Current Status of Development
Table 7.8 HDM201: Clinical Trials
Table 8.1 DUB based Therapeutics: Development Pipeline
Table 8.2 VLX 1570: Current Status of Development
Table 8.3 VLX 1570: Clinical Trials
Table 9.1 Velcade: Case Study
Table 9.2 Kyprolis: Case Study
Table 9.3 Ninlaro: Case Study
Table 9.4 IMiDs: Pipeline
Table 9.5 Thalomid: Case Study
Table 9.6 Revlimid: Case Study
Table 9.7 Pomalyst/Imnovid: Case Study
Table 9.8 Types of IAPs in Human Malignancies
Table 9.9 IAP Inhibitors: Pipeline
Table 9.10 AT 406/Debio 1143: Case Study
Table 9.11 Birinapant/TL 32711: Case Study
Table 10.1 List of Funding Instances and Investors, 2006-2016
Table 10.2 Types of Funding Instances, 2006-2016
Table 10.3 Amount Invested by Target Class, 2006- 2016 (USD Million)
Table 11.1 Ubiquitin Enzyme Inhibitors and Associated Products: Recent Collaborations (2006-2016)
Table 12.1 Ubiquitin Enzyme Inhibitors: Potential Candidates
Table 12.2 Idasanutlin: Target Patient Population
Table 12.3 Pevonedistat: Target Patient Population
Table 12.4 HDM201: Target Patient Population
Table 12.5 VLX1570: Target Patient Population
Table 12.6 AMG 232: Target Patient Population
Table 15.1 Ubiquitin Enzyme Inhibitors: Distribution by Phase of Development
Table 15.2 Ubiquitin Enzyme Inhibitors: Distribution by Therapeutic Area
Table 15.3 Ubiquitin Enzyme Inhibitors: Distribution by Target Enzymes
Table 15.4 Ubiquitin Enzyme Inhibitors: Distribution by Target Ubiquitin Enzymes and Phase of Development
Table 15.5 Ubiquitin Enzyme Inhibitors: Distribution by Geography
Table 15.6 Ubiquitin Enzyme Inhibitors: Most Active Industry Players
Table 15.7 Recent/Upcoming Conferences: Distribution by Year and Geography
Table 15.8 Funding Instances: Number of Instances, 2006-2016
Table 15.9 Funding Instances: Amount Invested, 2006-2016 (USD Million)
Table 15.10 Funding Instances: Distribution by Type, 2006-2016
Table 15.11 Funding Instances: Distribution by Total Amount Invested, 2006-2016 (USD Million)
Table 15.12 Most Active Players: Distribution by Number of Funding Instances, 2006-2016
Table 15.13 Most Active Venture Capital Firms/Investors: Distribution by Number of Instances, 2006-2016
Table 15.14 Funding Instances: Distribution by Focus Area
Table 15.15 Recent Collaborations: Distribution by Year
Table 15.16 Recent Collaborations: Distribution by Type of Model
Table 15.17 Recent Collaborations: Distribution by Focus Area
Table 15.18 Recent Collaborations: Distribution by Focus Area and Partnership Model
Table 15.19 Recent Collaborations: Most Active Players
Table 15.20 Overall Ubiquitin Enzyme Inhibitors Market (USD Million): 2016-2030 (Base Scenario)
Table 15.21 Overall Ubiquitin Enzyme Inhibitors Market (USD Million): 2016-2030 (Optimistic Scenario)
Table 15.22 Overall Ubiquitin Enzyme Inhibitors Market (USD Million): 2016-2030 (Conservative Scenario)
Table 15.23 Ubiquitin Enzyme Inhibitors: Market Distribution by Therapeutic Area, 2025, 2030 (USD Million)
Table 15.24 Ubiquitin Enzyme Inhibitors: Market Distribution by Target Enzyme Class, 2030 (USD Million)
Table 15.25 Ubiquitin Enzyme Inhibitors: Distribution of Market Share, 2030 (USD Million)
Table 15.26 Idasanutlin Sales Forecast (USD Million), Base Scenario
Table 15.27 Idasanutlin Sales Forecast (USD Million), Optimistic Scenario
Table 15.28 Idasanutlin Sales Forecast (USD Million), Conservative Scenario
Table 15.29 Pevonedistat Sales Forecast (USD Million), Base Scenario
Table 15.30 Pevonedistat Sales Forecast (USD Million), Optimistic Scenario
Table 15.31 Pevonedistat Sales Forecast (USD Million), Conservative Scenario
Table 15.32 HDM201 Sales Forecast (USD Million), Base Scenario
Table 15.33 HDM201 Sales Forecast (USD Million), Optimistic Scenario
Table 15.34 HDM201 Sales Forecast (USD Million), Conservative Scenario
Table 15.35 VLX1570 Sales Forecast (USD Million), Base Scenario
Table 15.36 VLX1570 Sales Forecast (USD Million), Optimistic Scenario
Table 15.37 VLX1570 Sales Forecast (USD Million), Conservative Scenario
Table 15.38 AMG 232 Sales Forecast (USD Million), Base Scenario
Table 15.39 AMG 232 Sales Forecast (USD Million), Optimistic Scenario
Table 15.40 AMG 232 Sales Forecast (USD Million), Conservative Scenario
Table 15.41 Ubiquitin Enzyme Inhibitors Market Summary (USD Million): 2016, 2023, 2030

Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • 3SBio
  • BostonBiochem
  • EG Capital Group
  • Invenio Therapeutics
  • Novitas Capital
  • Selleckchem
  • MORE

Research Methodology

Most of the data presented in this report has been gathered via secondary and primary research. For all our projects, we conduct interviews with experts in the area (academia, industry, medical practice and other associations) to solicit their opinions on emerging trends in the market. This is primarily useful for us to draw out our own opinion on how the market will evolve across different regions and technology segments. Where possible, the available data has been checked for accuracy from multiple sources of information.

The secondary sources of information include:

  • Annual reports
  • Investor presentations
  • SEC filings
  • Industry databases
  • News releases from company websites
  • Government policy documents
  • Industry analysts’ views

While the focus has been on forecasting the market over the coming ten years, the report also provides our independent view on various non-commercial trends emerging in the industry. This opinion is solely based on our knowledge, research and understanding of the relevant market gathered from various secondary and primary sources of information.
 
Chapter Outlines

Chapter 2 presents an executive summary of the report. It offers a high level view on where the ubiquitin enzyme inhibitors market is headed in the mid-long term.
 
Chapter 3 provides a general introduction to the underlying concepts of protein homeostasis, emphasizing on the importance of post translational modifications in cellular processes. The chapter covers details on the discovery of the UPS, the structure and function of ubiquitin, brief discussions on the various components of the UPS, fundamentals of the UPS machinery and a schematic representation of the ubiquitination process. In addition, we have discussed the therapeutic applications of the UPS, providing the necessary arguments and evidence supporting the gradual replacement of the currently available proteasome inhibitor based therapies with the emerging class of ubiquitin enzyme inhibitors.
 
Chapter 4 provides a comprehensive overview of the current landscape of the ubiquitin enzyme inhibitors market. It includes information on the potential drug candidates that are currently in different stages of development (both clinical and preclinical/discovery). It presents a detailed analysis of the pipeline of products in this domain, including information on the most commonly targeted indications, current phases of development, target enzyme classes and key players involved in this space. Additionally, we have provided details of several research platforms, precursor compounds and research tools developed/being developed by various companies in order to support R&D initiatives in this space.
 
Chapter 5 presents important insights extracted from the current pipeline. The chapter provides a grid analysis of the candidate drugs in the market based on their distribution by target enzyme class, therapeutic area and highest phase of development. It also highlights the most popular targets within the UPS pathway from among the four ubiquitin enzyme classes mentioned earlier. In addition, we have also included an overview of the developer landscape based on the size and the activity of the industrial/non-industrial players engaged in this market. Along with that, we have mapped the geographical presence of various companies involved in the clinical development of product candidates in this field.
 
Chapter 6 focuses on E1 activating enzyme and E2 conjugating enzyme based inhibitors. The chapter includes a brief discussion on the role of these enzymes in the UPS pathway, including their mechanisms of action, important enzyme families, targets under investigation, current challenges and opportunities, and other relevant parameters. The chapter also includes detailed profiles of advanced stage product candidates. Each profile covers information such as drug specifications, its mechanism of action, current status of development, ongoing/completed clinical studies, key preclinical/clinical findings and other associated details.
 
Chapter 7 provides in-depth information on E3 ligases. The chapter includes a brief discussion on the role of E3 ligases in the UPS pathway, including its mechanism of action, important enzyme families, targets under investigation, current challenges and opportunities, details of screening assays and other relevant parameters. The chapter also includes detailed profiles of advanced stage product candidates. Each profile covers information such as drug specifications, its mechanism of action, current status of development, ongoing/completed clinical studies, key preclinical/clinical findings and other associated details.
 
Chapter 8 elaborates on DUB enzyme inhibitors. As in earlier two chapters, it discusses the role of DUBs in the UPS pathway, including its mechanism of action, important enzyme families, targets under investigation, current challenges and opportunities, details of screening assays and other relevant parameters. The chapter also includes detailed profiles of the drugs under advanced stages of development.
 
Chapter 9 provides details on the various drug classes that are closely related to the UPS; these include proteasome inhibitors, immunomodulatory drugs (IMiDs) and inhibitors of apoptosis proteins (IAP inhibitors). In this section, we have provided a brief introduction to the aforementioned competing drug classes, providing insights into their respective mechanisms of action and an overview of the molecules developed/being developed under each class of drugs.
 
Chapter 10 presents details on the investments and grants received by companies working in the field of ubiquitin enzymes and other closely associated product candidates. The analysis highlights the growing interest of the venture capital community and other strategic investors in this market.
 
Chapter 11 features an elaborate discussion on the collaborations and partnerships that have been inked amongst players in this market. We have also discussed the various partnership models that have been implemented, highlighting the most common forms of deals/agreements prevalent in this segment of the overall market.
 
Chapter 12 provides a comprehensive market forecast analysis, highlighting the future potential of the market till the year 2030. The analysis takes into consideration the molecules that are in relatively more advanced stages of development (phase I/II, phase II and phase III). The future sales potential and growth opportunity is based on the target patient populations, existing/future competition, likely adoption rates and price points.
 
Chapter 13 summarizes the overall report. In this chapter, we have provided a recap of the key takeaways from the study and our independent opinion based on the research and analysis described in previous chapters.
 
Chapter 14 is a collection of interview transcripts of the discussions that were held with key stakeholders in this market. We have presented the details provided to us by Martin Wiles (Vice President, Almac Discovery) and Gerald Gavory (Director of Biology, Almac Discovery), Zhihao Zhuang (Associate Professor, Department of Chemistry and Biochemistry, University of Delaware) and Katrin Rittinger (Research Group Leader, Francis Crick Institute).
 
Chapter 15 is an appendix, which provides tabulated data and numbers for all the figures provided in the report.
 
Chapter 16 is an appendix, which provides the list of companies and organizations mentioned in the report.

Note: Product cover images may vary from those shown
5 of 5
  • 3SBio
  • 5AM Ventures
  • ARCH Venture Partners
  • Abbiotec
  • Abcam
  • AcelRx Pharmaceuticals
  • Aegera Therapeutics
  • Aeneas Ventures
  • Agilis Biotherapeutics
  • Aileron Therapeutics
  • Aju IB Investment
  • Alexion Pharmaceuticals
  • Almac Discovery
  • Amgen
  • Angelman Syndrome Foundation
  • Apeiron Biologics
  • Apple Tree Partners
  • Arcus Ventures
  • Argenta Discovery
  • Argos Soditic
  • Arvinas
  • Ascenta Therapeutics
  • Ascentage Pharma
  • Astellas Venture Management
  • Astex Pharmaceuticals
  • AstraZeneca
  • Australasian Leukemia and Lymphoma Group
  • Avacta
  • BPS Biosciences
  • Bavarian Research Foundation
  • Bio-Techne
  • BioTheryx
  • Biogen
  • Biogenova
  • Biotechnology and Biological Sciences Research Council
  • Boehringer Ingelheim
  • Boston Biochem
  • Boston University Technology Development...
  • BostonBiochem
  • Business Development Bank of Canada
  • Business Development Corporation (BDC) Capital
  • C4 Therapeutics
  • CMEA Ventures
  • Calculus Capital
  • Canaan Partners
  • Cancer Research Technology
  • Captor Therapeutics
  • Carmot Therapeutics
  • Cayman Chemicals
  • Celgene Corporation
  • Cell Signaling Technology
  • CellCentric
  • CellXplore
  • Cellivery Therapeutics
  • Celon Laboratories
  • Chinese University of Hong Kong
  • Cisbio Bioassays
  • Clarus Ventures
  • Cleave Biosciences
  • Cobro Ventures
  • Columbia University
  • Comprehensive Cancer Center of Wake Forest University
  • Connecticut Innovations
  • Cormorant Asset Management
  • Curis
  • Cyclofluidic
  • Daiichi Sankyo
  • Dana-Farber Cancer Institute
  • Debiopharm
  • Desjardins Venture Capital
  • Deutsche Bank
  • Domain Associates
  • Dr. Reddy's
  • Draper Esprit
  • Draper Fisher Jurvetson
  • E3X Bio
  • EG Capital Group
  • Edmond de Rothschild Investment Partners
  • Elan Pharmaceuticals
  • Elm Street Ventures
  • Encycle Therapeutics
  • Endeavour Vision
  • Ensemble Therapeutics
  • Enterprise Partners
  • Enzo Lifesciences
  • Erimos Pharmaceutical
  • Excel Venture Management
  • F-Prime Capital Partners
  • Flagship Ventures
  • Focus Biomolecules
  • Forma Therapeutics
  • Foundation Venture Capital Group
  • Foundation for Angelman Syndrome Therapeutics (FAST)
  • Fox Chase Cancer Center
  • Francis Crick Institute
  • Genentech (Hoffmann-La Roche)
  • GlaxoSmithKline
  • GrowthWorks Capital
  • Halle University
  • Harris & Harris Group
  • Harvard Medical School
  • Hasso Plattner Ventures
  • Hatteras Venture Partners
  • HealthCare Ventures
  • Horizon Discovery
  • Human Genome Sciences
  • Hybrigenics
  • IP Group
  • Imperial Innovations
  • Index Ventures
  • Innovate UK
  • Intrexon
  • Invenio Therapeutics
  • Investissement Québec
  • Janssen Research & Development
  • Kamiya Biomedical Company
  • Karolinska Institute
  • Laboratorio Varifarma
  • Latterell Venture Partners
  • Life Technologies
  • LifeSensors
  • Ligand Pharmaceuticals
  • Lilly Ventures
  • Linköping University
  • Lurie Investment Fund
  • MVM Life Science Partners
  • MaRS Investment Accelerator Fund
  • Majuven
  • Makoto Life Sciences
  • Mayo Clinic
  • Medical Research Council
  • Memorial Sloan Kettering Cancer Center
  • Merck
  • Meso Scale Discovery
  • MiRx Pharmaceuticals
  • Michael J. Fox Foundation
  • Millennium Pharmaceuticals
  • Miltenyi Biotec
  • Mission Therapeutics
  • Morningside Venture Investments
  • Mount Sinai Hospital’s Lunenfeld-Tanenbaum Research Institute
  • Multiple Capital
  • Natco Pharma
  • National Cancer Institute
  • National Institutes of Health Small Business Innovation Research
  • New Enterprise Associates
  • New Leaf Venture Partners
  • New York University
  • Nextech Invest
  • Novartis Pharmaceuticals
  • Novitas Capital
  • Novus Biologics
  • Nurix
  • Nxt2b
  • Ono Pharmaceutical
  • Onyx Pharmaceuticals
  • OrbiMed
  • Osage University Partners
  • Oxford Bioscience Partners
  • Parkwalk Advisors
  • Peloton Therapeutics
  • Penn Pharmaceutical Services
  • PerkinElmer
  • Perrigo Company
  • Perseus
  • Pfizer
  • Pharmascience
  • Pharmion Corporation
  • Priaxon
  • Progenra
  • Promega
  • Proteologics
  • Proteostasis Therapeutics
  • Proteros Biostructures
  • Providence Investment Company
  • Quaker BioVentures
  • Queen’s University
  • R & D Systems
  • RA Capital Management
  • Remeditex Ventures
  • Rigel Pharmaceuticals
  • Roche
  • Roswell Park Cancer Institute
  • SR One
  • SV Life Sciences
  • Sanofi
  • Sanofi-Genzyme BioVentures
  • Santa Cruze Biotech
  • Scottish Investment Bank (Investment Arm of Scottish Enterprise)
  • Selleckchem
  • Sequoia Capital
  • Servier
  • Sidney Kimmel Comprehensive Cancer Center
  • Sigma-Aldrich
  • Sofinnova Ventures
  • Statsyuk Research Group
  • Stemgent
  • Supergen
  • Taiho Pharmaceutical
  • Takeda
  • Tensha Therapeutics
  • TetraLogic Pharmaceuticals
  • The Column Group
  • Thermo Fisher Scientific
  • Thiel Foundation’s Breakout Labs
  • Third Rock Ventures
  • Tocris
  • Tokyo Medical University
  • UBP Biotech
  • UbiQ Therapeutics
  • Ubiquigent
  • Universities of Toronto and Sherbrooke
  • University of Birmingham
  • University of Cambridge Enterprise
  • University of Delaware
  • University of Dundee
  • University of Florida
  • University of Glasgow
  • University of Liverpool
  • University of Michigan
  • University of Oxford
  • University of Rome “Tor Vergata”
  • University of South Florida (USF)
  • University of Texas
  • University of Toronto
  • Université de Montréal
  • VenGrowth Capital Partners
  • Vivolux
  • Walter and Eliza Hall Institute of Medical Research
  • Woodford Patient Capital Trust
  • Wren Capital
  • Yale University
  • Yonsei University College of Medicine
  • Yorkville Advisors
Note: Product cover images may vary from those shown
6 of 5
Note: Product cover images may vary from those shown
Adroll
adroll